By-health Co., Ltd. (300146.SZ) Bundle
From its founding in Guangzhou on October 28, 1995 as Guangdong By-Health Biotechnology Co., Ltd., Byhealth Co., Ltd. (ticker 300146) has grown into a public player that went public on the Shenzhen Growth Enterprise Market on December 15, 2010 and-by July 1, 2025-commanded a market capitalization of about CN¥19.39 billion; leveraging celebrity endorsement, transparent manufacturing such as the 2012 Zhuhai Transparent Factory, and a product mix spanning protein powders, collagen, bone-health formulas and multivitamins sold via pharmacies, supermarkets and e-commerce, the company operates with roughly 2,955 employees and held an estimated 9.3% market share in China's supplement market in 2024, even as it faced headwinds in 2024 with a 27.3% year-on-year revenue decline and a 62.62% drop in net profit attributable to shareholders, prompting strategic moves in 2025 including an OTC launch (Keylid Glucosamine Sulfate) and expansion into Southeast Asian infant nutrition markets to defend and rebuild its position
By-health Co., Ltd. (300146.SZ): Intro
History By-health Co., Ltd. (300146.SZ) was established on October 28, 1995, in Guangzhou as Guangdong By-Health Biotechnology Co., Ltd. Key milestones:- 2002 - Systematically introduced vitamins and dietary supplements into China's non-direct-marketing sector, expanding product reach beyond traditional channels.
- 2010 - Secured an endorsement from Yao Ming, driving rapid consumer recognition and household-brand status.
- 2010-12-15 - IPO on the Shenzhen Stock Exchange Growth Enterprise Market (ticker: 300146), providing growth capital and market visibility.
- 2012 - Opened the Zhuhai Transparent Factory, an open-manufacturing initiative to demonstrate product integrity and production transparency.
- 2025 - Marked the company's 30th anniversary, reflecting three decades of expansion in the Chinese dietary-supplement market.
- Public listing (SZSE: 300146) provides transparent reporting and regulatory oversight under China Securities Regulatory Commission rules.
- Major ownership blocs historically include founder/management-related holdings, strategic corporate investors, and mutual/asset-management firms; active institutional ownership has increased since listing.
- Board and management emphasize R&D and quality-control oversight tied to the Zhuhai manufacturing footprint and branded-product strategy.
- Brand-first approach: national marketing campaigns, celebrity endorsement history, and consumer trust building (e.g., Zhuhai Transparent Factory).
- Multi-channel distribution: e-commerce, Tmall/JD and cross-border platforms, traditional retail, pharmacies and institutional sales.
- Product innovation and quality: R&D investment in vitamins, probiotics, minerals, and specialized nutrition; certified GMP/quality systems.
- Export and licensing: selective overseas expansion and private-label/OEM opportunities leveraging manufacturing scale.
- R&D and product formulation teams design supplements across vitamins, minerals, herbal and probiotic categories.
- Manufacturing network includes the Zhuhai Transparent Factory-used as a quality and marketing asset-plus other GMP-compliant facilities.
- Sales channels blend direct e-commerce (company stores and marketplaces), third-party retail/pharmacy distribution, and export/OEM customers.
- Marketing mixes mass-media campaigns, celebrity endorsements, KOL/digital marketing and in-store pharmacy partnerships to drive trust and repeat purchase.
- Retail sales of branded dietary supplements (core): vitamins, minerals, probiotics and specialty nutrition products.
- E-commerce and marketplace sales (growing share with higher margin segments through direct-to-consumer channels).
- Wholesale/pharmacy distribution and institutional sales.
- OEM/private-label manufacturing and selective export sales.
| Metric | 2022 (approx.) | 2023 (approx.) |
|---|---|---|
| Revenue (RMB) | ≈ 6.9 billion | ≈ 7.5 billion |
| Net profit (RMB) | ≈ 1.16 billion | ≈ 1.30 billion |
| Total assets (RMB) | ≈ 12.5 billion | ≈ 13.2 billion |
| Gross margin | mid-40% range | mid-40% range |
| Market capitalization (approx., 2024) | ≈ 60 billion RMB | |
- Product mix: higher-margin proprietary branded SKUs and premium formulations lift gross margin relative to low-margin commodity supplements.
- Channel mix: direct e-commerce reduces intermediary fees and improves customer LTV; retail/pharmacy maintains reach and recurrent sales.
- Scale in manufacturing: in-house GMP facilities improve cost control and enable OEM revenue diversification.
- Brand equity and trust (transparency initiatives, endorsements) sustain pricing power and repeat purchase rates.
By-health Co., Ltd. (300146.SZ): History
By-health Co., Ltd. (300146.SZ) was founded as a nutritional supplements and health products manufacturer and grew through a mix of product innovation, M&A and broad retail distribution. Listed on the Shenzhen Stock Exchange, the company has expanded from domestic OTC channels into e-commerce and cross-border sales, positioning itself as a major player in China's health supplement sector.- Public listing: Shenzhen Stock Exchange, ticker 300146.SZ.
- Market capitalization (as of July 1, 2025): CN¥19.39 billion.
- Investor base: mix of institutional and retail shareholders, reflecting broad ownership.
- Major holders: founders and key executives retain material shareholdings, providing continuity and strategic alignment.
- Governance: board and management structures oriented toward shareholder value and long-term growth.
| Metric | Value (most recent fiscal year) |
|---|---|
| Revenue | CN¥7.2 billion |
| Net profit | CN¥0.9 billion |
| Total assets | CN¥12.5 billion |
| Market capitalization (Jul 1, 2025) | CN¥19.39 billion |
| Largest shareholder block (founders & execs) | Significant single-digit to low-double-digit % stakes (combined) |
- Mission: develop science-backed nutritional products that support consumer health across life stages.
- How it works / business model:
- R&D and product formulation in-house and via partners.
- Manufacturing across proprietary and contracted facilities.
- Multi-channel sales: pharmacy/retail, e-commerce platforms, cross-border channels, and institutional sales.
- Branding, regulatory compliance and marketing to drive premium pricing and repeat purchases.
- Revenue drivers: new product launches, channel expansion (especially online), export growth, and margin management through scale.
- Governance & alignment: insider stakes plus institutional holders underpin continuity; governance practices target alignment of management incentives with shareholder returns.
By-health Co., Ltd. (300146.SZ): Ownership Structure
By-health Co., Ltd. (300146.SZ) mission is to provide the highest-quality vitamin and dietary supplements to families and friends, emphasizing a commitment to consumer health. The company operates with a strong emphasis on integrity, transparency, and responsibility to build trust with consumers and stakeholders. Innovation drives product development and solutions to meet evolving consumer needs, while agility ensures rapid response to market dynamics. By-health fosters a culture of respect and enjoyment, valuing every individual and promoting a positive work environment. Its values are encapsulated in its DNA: science-based nutrition, global raw materials, transparent manufacturing, and a focus on families and friends.- Mission: Deliver high-quality vitamins and dietary supplements focused on family and friend health.
- Core values: integrity, transparency, responsibility, innovation, agility, respect.
- DNA pillars: science-based nutrition; global raw material sourcing; transparent manufacturing; family-and-friend focus.
| Ownership Category | Typical Stake Range | Role / Notes |
|---|---|---|
| Founders & Management | Significant minority (board-aligned) | Strategic direction, product R&D oversight |
| Corporate/Strategic Investors | Large single-digit to low double-digit % | Supply-chain partnerships, raw material agreements |
| Institutional Investors | High single-digit to ~30% collectively | Provide liquidity and governance monitoring |
| Retail Public Float | Remainder (~30-60%) | Day-to-day market liquidity and price discovery |
- How it makes money: product sales across direct-to-consumer channels, e-commerce platforms, retail distribution, and B2B supply contracts for raw materials and finished supplements.
- Revenue drivers: new product launches, premiumization (higher-margin formulations), channel mix shift to online, and export growth.
- Economic model focus: gross margin protection via supply-chain sourcing, marketing-driven customer acquisition, and recurring-purchase retention strategies.
By-health Co., Ltd. (300146.SZ): Mission and Values
By-health Co., Ltd. (300146.SZ) is a leading Chinese nutritional supplements company focused on research, development, production and sales of dietary supplements designed for general consumers, maternal & child, sports nutrition and senior health segments. The company's core mission emphasizes evidence-backed nutrition, product safety, and broad accessibility to improve public health outcomes. Mission Statement, Vision, & Core Values (2026) of By-health Co., Ltd. How It Works- Research & Development: By-health operates centralized R&D capabilities that develop formulas across vitamins, minerals, proteins and specialty nutraceuticals (collagen, glucosamine, chondroitin and calcium combinations).
- Manufacturing: The company controls production with GMP-standard facilities to ensure quality, shelf-stability and regulatory compliance for dietary supplements sold in China and selected export markets.
- Product Portfolio: Offerings span protein powders, collagen products, bone health supplements (including glucosamine-chondroitin-calcium tablets), multivitamins, probiotics, and targeted maternal & child nutrition.
- Brand Architecture: Products are marketed under multiple brands to address different demographics and positioning-most notably By-Health (core brand), Jianliduo (value / specialty lines), and Lifespace (where applicable through partnership/licensing).
- Distribution & Sales: A hybrid distribution model combines traditional offline retail and modern e-commerce to maximize reach across urban and lower-tier cities.
- Offline retail: pharmacies, supermarkets, convenience chains and maternal & child specialty stores.
- Online marketplaces: Tmall, JD.com, Vipshop.
- Short-video/live-commerce platforms: Douyin and Kuaishou for branded stores and influencer-driven sales.
- Institutional and cross-border channels: selected healthcare institutions and export partners for specific SKUs.
| Metric | Value |
|---|---|
| Listed ticker | 300146.SZ |
| Employees (approx.) | 2,955 |
| Core brands | By-Health, Jianliduo, Lifespace |
| Main product categories | Protein powders, collagen, bone health (glucosamine-chondroitin-calcium), multivitamins, probiotics |
| Primary e-commerce platforms | Tmall, JD.com, Vipshop, Douyin, Kuaishou |
| Offline retail channels | Pharmacies, supermarkets, maternal & child stores |
- Direct product sales: Core revenue derived from selling finished dietary supplement SKUs through offline retailers and online marketplaces.
- Channel mix optimization: Higher-margin sales through proprietary e-commerce stores and short-video/live commerce; volume-driven, lower-margin distribution via mass retail and pharmacy chains.
- Premiumization: Launch of premium formulations (e.g., high-purity collagen, specialty sports protein) to capture higher ASP (average selling price) and margin uplift.
- Private label & partnerships: Co-development and B2B supply arrangements for third-party brands and institutional buyers.
- Promotion & marketing economics: Significant investment in DTC marketing, KOL/influencer partnerships and seasonal promotions to drive traffic and conversion on digital channels.
By-health Co., Ltd. (300146.SZ): How It Works
By-health Co., Ltd. (300146.SZ) operates as one of China's largest nutritional supplement manufacturers, converting R&D, manufacturing, distribution and marketing into recurring sales across a broad consumer base. Its business model centers on product innovation, brand trust, diversified channel distribution and large-scale manufacturing efficiencies.- Core revenue drivers: sale of dietary supplements across categories such as protein powders, collagen, bone & joint health, omega-3/fish oil, probiotics and multivitamins.
- Multiple distribution channels: pharmacy chains, supermarkets, specialty health stores, direct retail, and major e-commerce platforms (Tmall, JD.com, Pinduoduo and brand-owned online stores).
- Value creation: strong brand recognition, quality control (GMP/ISO practices), product differentiation (ingredient formulations, targeted consumer segments) and marketing/endorsement strategies that drive repeat purchases.
- R&D and new product pipeline: continuous launches of targeted formulations (e.g., aging, maternal & infant, sports nutrition) to capture expanding health-conscious demographics.
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Total revenue (RMB) | 6.20 billion | 7.10 billion | 8.20 billion |
| Net profit (RMB) | 0.95 billion | 1.05 billion | 1.35 billion |
| Gross margin | 56% | 55% | 54% |
| E-commerce share of sales | 48% | 52% | 57% |
| Offline channel share of sales | 52% | 48% | 43% |
- Product portfolio weighting (approximate): multivitamins & general supplements ~28%, maternal & infant nutrition ~22%, sports & protein products ~18%, bone & joint & collagen ~17%, specialty (probiotics, immune) ~15%.
- Channel economics: e-commerce yields higher contribution margins due to lower middle-channel fees despite heavier promotional spend; pharmacy/supermarket channels provide stable volume and customer trust.
- Average selling price (ASP): varies by category-premium collagen and maternal formulas command higher ASPs (RMB 150-500 per SKU) versus mass-market vitamins (RMB 30-120 per SKU).
- Distribution network: nationwide footprint via thousands of chain pharmacies and supermarkets plus direct partnerships with major e-commerce marketplaces, enabling rapid product rollouts and geographic penetration.
- Manufacturing capacity: owned production facilities and strategic OEM partnerships to flex capacity for seasonal and campaign-driven demand.
- Marketing & trust: investment in clinical-backed claims, strategic KOLs/celebrity endorsements, membership/loyalty programs and health-education content to boost repeat purchase rates.
- Innovation pipeline: annual R&D investment targeted at new formulations, delivery formats (chewables, gummies, liquid shots) and packaging to expand addressable market segments.
- Gross margin management through procurement scale of active ingredients and formulation standardization.
- Channel mix optimization-shifting toward higher-margin e-commerce while maintaining offline presence for discovery and trust.
- Promotional ROI focus-balancing short-term acquisition discounts with long-term customer lifetime value via subscriptions and membership retention.
- Product lifecycle management-sunsetting low-velocity SKUs and reallocating shelf/advertising to high-velocity, high-margin innovations.
By-health Co., Ltd. (300146.SZ): How It Makes Money
By-health Co., Ltd. (300146.SZ) is a leading Chinese manufacturer and marketer of vitamins, minerals, dietary supplements, and nutrition products. Founded in 1995 and listed in Shenzhen, the company combines R&D, manufacturing, branding and multi-channel distribution to monetize scientific formulations and strong brand recognition. Major shareholders include institutional investors and founding management (ownership stakes vary with filings).- Market share in China's vitamin & dietary supplement category: ~9.3% (2024).
- Main revenue drivers: consumer supplement sales (online & offline), infant nutrition, and prescription/OTC pipeline products.
- Key new product: Keylid Glucosamine Sulfate - first OTC launch planned for 2025 to enter adjacent therapeutic OTC market.
| Metric | 2023 | 2024 | YoY Change |
|---|---|---|---|
| Total Revenue (CNY) | 7,820,000,000 | 5,693,460,000 | -27.3% |
| Net Profit Attributable to Shareholders (CNY) | 1,200,000,000 | 446,760,000 | -62.62% |
| China Market Share | - | 9.3% | - |
- Direct-to-consumer sales via e-commerce platforms (company stores, major marketplaces).
- Retail and pharmacy distribution across offline chains and independent stores.
- B2B/international exports, increasingly focused on Southeast Asia (infant nutrition push).
- New OTC and specialty product launches to expand margins and address regulatory pathways.
- Offensive: invest in high-quality SKUs (infant nutrition, OTC Keylid) and geographic expansion in SE Asia to capture local demand.
- Defensive: optimize channels, reduce low-return SKUs, and strengthen brand loyalty to stem margin erosion from intensified competition.
- Efficiency moves: capex for manufacturing scale, SKU rationalization, and marketing ROI improvements to restore profitability.
- 2024 revenue fell 27.3% YoY; net profit down 62.62% YoY-indicative of margin compression and inventory/marketing adjustments.
- Competition: intensified pressure from multinational supplement brands and agile domestic rivals affecting pricing and shelf share.
- International expansion target: Southeast Asia, with infant nutrition products positioned to leverage demographic demand and premiumization trends.
By-health Co., Ltd. (300146.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.